Evidence Level
Moderate
Bergamot research has accelerated rapidly since the pivotal Mollace et al. (2011) study demonstrated impressive LDL and triglyceride reductions in hyperlipidemic patients. Gliozzi et al. (2014) extended these findings to metabolic syndrome, showing improvements across multiple cardiometabolic markers. The mechanisms are well-characterized: brutieridin and melitidin directly inhibit HMG-CoA reductase (the same target as statins), while other polyphenols activate AMPK and improve glucose uptake. Most studies use Calabrian bergamot extracts, and product quality varies significantly — standardized BPF from authenticated Citrus bergamia sources provides the most reliable results.